Astral Systems aims to raise £23 million to focus on cancer isotopes.

      Bristol-based fusion startup Astral Systems has secured £23 million to expand the production of medical isotopes essential for cancer scans. This funding round, which supports a rare fusion company that currently operates reactors and generates revenue, positions Astral as a different player in the field compared to most fusion companies that anticipate delivering clean energy in a decade or two, as Astral is already generating income.

      The Bristol startup has completed the initial tranche of a £23 million Series A funding round led by Mercia Ventures. This round boosts its overall funding to over £28 million. The raised funds will enhance the production of radioactive isotopes used in the diagnosis and treatment of cancer, addressing a market characterized by a fragile supply chain and a scarcity of UK sources.

      Tees River, Daphni, and Blast Club participated in this funding round, alongside returning investors Speedinvest and Playfair, reflecting a robust year for venture funding in the UK.

      The issue of the supply chain is largely unrecognized. Annually, over 50 million cancer scans and treatments depend on radioisotopes, which are produced by bombarding raw materials with neutrons in reactors. Most of these reactors are several decades old and located in a limited number of countries, with the UK hardly producing any isotopes.

      The risks associated with this reliance are real; in 2009 and 2010, simultaneous shutdowns of reactors in Canada and the Netherlands led to shortages for hospitals across Europe and North America.

      Founded in 2021 by CEO Talmon Firestone and CTO Tom Wallace-Smith, Astral has developed a reactor utilizing a design it terms "multi-state fusion." This technology integrates various fusion states within a single unit to generate intense neutron beams for isotope production. Unlike many in the sector, Astral is already operational, with three commercial fusion facilities and research contracts exceeding £3 million.

      Collaborating with McMaster University and a Brazilian nuclear research institute, Astral is developing two isotopes for targeted cancer therapy, Actinium-225 and Lead-212, with plans to have at least one available in the market by early 2027.

      The capital raised will finance operations at the former Berkeley Power Station in Gloucestershire, a decommissioned plant equipped with grid connections and nuclear-grade infrastructure. Astral intends to have several next-generation reactors fully operational at this site by the end of 2026, targeting profitability by 2027 and expanding its team from 23 to over 40 employees. Two senior scientists have recently joined the team: NASA Laureate Theresa Benyo as chief research officer and chief scientist Mahmoud Bakr.

      Astral faces competition in addressing the isotope shortage. In the US, SHINE Technologies has raised over $1 billion and operates a large facility producing Lutetium-177, while Niowave employs electron accelerators for isotope production. Although these companies are further along commercially, neither caters to the UK market.

      Astral contends that its technology can produce a broader range of isotopes at a modular scale, in contrast to the fusion sector, which is primarily focused on long-term power solutions. Firestone stated, “We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company.”

      Lee Lindley, who led the investment at Mercia, emphasized the commercial appeal of Astral rather than the scientific aspects, calling it “a perfect example of the bold ideas that Mercia likes to back.”

      The potential rewards are significant, as the global nuclear medicine market was valued at $17.77 billion in 2024 and could grow to $34.51 billion by 2030, according to Grand View Research. The critical aspect moving forward will be execution, as Astral must scale its innovative reactors at a former power station while achieving its profitability goal by 2027. Success in this endeavor could mark the beginning of the first commercial phase of British fusion, not through clean energy but via cancer treatment.